CARLSBAD, CA – Nov. 2, 2010 -- Life Technologies Corporation, a provider of innovative life science solutions, today announced the launch of a gene-cloning platform that enables researchers to efficiently assemble up to 10 synthetic or pre-existing DNA fragments in yeast (in vivo) to create a seamless sequence up to 110 kilo base pairs (kbp) in length – a first in the marketplace.

Life Technologies’ GENEART® High-Order Genetic Assembly System capitalizes on yeast cells’ natural ability to take up and assemble DNA fragments to produce a customized molecule into a vector of choice before it can be transferred into E. coli for downstream applications.

Current commercial cloning products lack the robustness and flexibility that’s needed to assemble very large sequences, and traditionally require complicated strategies that can take weeks to assemble complex and large molecules.  The process using GENEART® High-Order Genetic Assembly System involves less than 30 minutes of prep work and three days of incubation to obtained the assembled molecule.

“This novel kit offers a highly valuable solution and meets a need that until now has not been commercially available for researchers in the synthetic and molecular biology fields,” said Jaime Humara, Senior Product Manager for Life Technologies.  “The flexibility to easily customize DNA sequences at much higher scales than ever before will put scientists at a significant advantage in their research endeavors.”

The seamless construct is enabled by DNA fragments with end-homology. In cases where end-homology does not exist, synthetic oligonucleotides, or DNA linkers, can be designed so that the yeast cells can ‘stitch’ the fragments together into a seamless sequence. 

A free, web-based tool on the Invitrogen site has also been developed to assist customers plan and design their experiment. After entering the various sequences of interest, the web tool automatically checks for potential homology issues that may impede proper assembly into a vector, and presents the user with a final annotated sequence and graphical representation of the assembled molecule. With a click of the mouse, customers can then order their DNA oligonucleotides and the GENEART® High-Order Assembly System with all the necessary reagents to start their experiment.

For smaller constructs, the GENEART® Seamless Cloning and Assembly Kit is also being introduced as part of this launch.  It offers an in vitro solution optimized to clone up to four linear DNA fragments, totaling up to 13 kbp, into virtually any vector.

These gene-cloning solutions are part of Life Technologies’ larger strategic initiative to expand its presence and provide tools in the rapidly evolving synthetic biology market, which is estimated to reach up to $2.4 billion by 2013, according to a report by BCC Research. By providing highly efficient and reliable tools and services, Life Technologies is enabling researchers around the world to address new technology applications in energy, chemical production, bioremediation and agriculture.

Representatives from Life Technologies and GENEART will give presentations, titled Next Generation Assembly Tools, and The Better Way to Get Your DNA: Rationales of gene design, de novo gene synthesis and their applications, respectively, at the 2010 International Genetically Engineered Machine (iGEM) competition on Nov. 6 at MIT.

About Life Technologies (www.lifetechnologies.com)
Life Technologies Corporation (NASDAQ: LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit our website: http://www.lifetechnologies.com.

Life Technologies’ Safe Harbor Statement
This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies’ plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words “believe,” “plan,” “intend,” “anticipate,” “target,” “estimate,” “expect” and the like, and/or future tense or conditional constructions (“will,” “may,” “could,” “should,” etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances.

Life Technologies Contact
Mauricio Minotta
760-929-2456

Mauricio.minotta@lifetech.com